Asset Details
Do you wish to reserve the book?
Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B
Do you wish to request the book?
Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B
2019
Overview
Abnormal alternative splicing (AS) caused by alterations to splicing factors contributes to tumor progression. Serine/arginine splicing factor 1 (SRSF1) has emerged as a key oncodriver in numerous solid tumors, leaving its roles and mechanisms largely obscure in glioma. Here, we demonstrate that SRSF1 is increased in glioma tissues and cell lines. Moreover, its expression was correlated positively with tumor grade and Ki-67 index, but inversely with patient survival. Using RNA-Seq, we comprehensively screened and identified multiple SRSF1-affected AS events. Motif analysis revealed a position-dependent modulation of AS by SRSF1 in glioma. Functionally, we verified that SRSF1 promoted cell proliferation, survival, and invasion by specifically switching the AS of the myosin IB (MYO1B) gene and facilitating the expression of the oncogenic and membrane-localized isoform, MYO1B-fl. Strikingly, MYO1B splicing was dysregulated in parallel with SRSF1 expression in gliomas and predicted the poor prognosis of the patients. Further investigation revealed that SRSF1-guided AS of the MYO1B gene increased the tumorigenic potential of glioma cells through the PDK1/AKT and PAK/LIMK pathways. Taken together, we identify SRSF1 as an important oncodriver that integrates AS control of MYO1B into promotion of gliomagenesis and represents a potential prognostic biomarker and target for glioma therapy.
Publisher
American Society for Clinical Investigation
Subject
/ Animals
/ Arginine
/ Brain Neoplasms - metabolism
/ Cell Transformation, Neoplastic - genetics
/ Cell Transformation, Neoplastic - metabolism
/ Cell Transformation, Neoplastic - pathology
/ Female
/ Gene Expression Regulation, Enzymologic
/ Gene Expression Regulation, Neoplastic
/ Genes
/ Genomes
/ Glioma
/ Gliomas
/ Humans
/ Kinases
/ Male
/ Mice
/ Myosin
/ Myosin Type I - biosynthesis
/ RNA
/ Roles
/ Serine
/ Serine-Arginine Splicing Factors - genetics
/ Serine-Arginine Splicing Factors - metabolism
/ Signal Transduction - genetics
/ Tumors
